ASSENT-3: Implications for future trial design and clinical practice

European Heart Journal

Volumn 23, Issue 12, 2002, Pages 911-912

  Van de Werf, F ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TENECTEPLASE;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE II; CONTROLLED CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RESEARCH DESIGN; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0036623914     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3048     Document Type: Editorial

References (11)

1. Ross AM, Molhoek P, Lundergan C et al. A randomised comparison of low-molecular-weight heparin enoxaparin and unfractionated heparin adjunctive to t-PA thrombolysis and aspirin (HART II). Circulation 2001; 104: 648-52.
2. Simoons ML, Alonso A, Krzeminska-Pakula M et al. Early ST segment elevation resolution: Predictor of outcome and angiographic patency in patients with acute myocardial infarction. Results of the AMI-SK study. Eur Heart J (in press).
3. Baird SH, McBride SJ, Trouton TG, Wilson C. LMWH versus unfractionated heparin following thrombolysis in myocardial infarction (Abstr). J Am Coll Cardiol 1998; 31 (Suppl A): 191A.
4. Wallentin L, Dellborg DM, Lindahl B et al. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT Plus study. Clin Cardiol 2001; 24 (Suppl 3): 112-14.
5. Antman EM, Giugliano RP, Gibson CM et al., for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. Circulation 1999; 99: 2720-32.
6. The SPEED Group (Strategies for the Patency Enhancement in the Emergency Department). Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788-94.
7. Brener SJ, Vrobel TR, Lopez JF et al. INTRO AMI: Marked enhancement of arterial patency with eptifibatide and low-dose t-PA in acute myocardial infarction (Abstr). Circulation 1999; 100 (Suppl): 1-649.
8. The ASSENT-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
9. Ryan TJ, Antman EM, Brooks NH et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100: 1016-30.
10. The GUSTO V investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001; 357: 1905-14.
11. The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-22.